Malik Prabhat Singh, Jain Deepali, Kumar Lalit
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, New Delhi, India.
Oncology. 2016;91 Suppl 1:26-34. doi: 10.1159/000447578. Epub 2016 Jul 28.
The advent of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has led to a paradigm shift in the management of advanced adenocarcinoma of the lung. The key to success of these therapies lies in the precise identification of their molecular targets, i.e. sensitizing EGFR mutations. The variations in the prevalence of these mutations among different ethnicities necessitate regional studies for a better understanding of the molecular epidemiology of the disease and clinical decision-making. This is even more relevant for countries like India where genetic heterogeneity is a rule. Here, we make an attempt to review the epidemiology of EGFR mutations in India versus other Asian countries and the West. We also review the clinical experience with EGFR TKIs and suggest the way forward in a resource-limited setting.
表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）的出现，使晚期肺腺癌的治疗模式发生了转变。这些疗法成功的关键在于精确识别其分子靶点，即敏感的EGFR突变。不同种族间这些突变发生率的差异，使得开展地区性研究以更好地了解该疾病的分子流行病学及临床决策变得必要。这对于像印度这样基因异质性普遍存在的国家而言更为重要。在此，我们尝试回顾印度与其他亚洲国家及西方国家EGFR突变的流行病学情况。我们还回顾了EGFR TKIs的临床经验，并提出在资源有限的情况下的未来发展方向。
